Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal
Venture investors who saw the company through a failed IPO attempt receive long-awaited returns from a $425 million upfront payment.
Venture investors who saw the company through a failed IPO attempt receive long-awaited returns from a $425 million upfront payment.